Fig. 3: Autologous HSCT using E6V-corrected SCD HSCs can correct erythropoiesis in vivo. | Nature Communications

Fig. 3: Autologous HSCT using E6V-corrected SCD HSCs can correct erythropoiesis in vivo.

From: Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice

Fig. 3

A Half-life of EZH-biotin labeled Ter119+ PB RBCs, relative to labeling 24 h post-injection of EZH-biotin (RBC labeling efficiency at ~50%). Non-transplanted HbS and HbA mice included as controls. B Representative flow cytometric plots for Biotin vs Ter119 for Ter119+ PB RBCs at day 30 post-injection of EZH-biotin displayed in (A) and a no EZH-biotin injection control. C Representative Wright-Giemsa staining for PB from a non-transplanted HbS mouse, gene-corrected HSCT recipient (Mouse A), and a non-transplanted HbA mouse. Examples of abnormal RBC morphology indicated with white arrows. Representative for PB from Mouse A and Mouse B. Black scale bars indicate 50 µm. D Representative images of metabisulphite sickling assays performed on PB from a non-transplanted HbS mouse, gene-corrected HSCT recipient (Mouse A), and a non-transplanted HbA mouse. Abnormal RBC morphology indicated with white arrows. Representative for PB from Mouse A and Mouse B. Black scale bars indicate 50 µm. Source data are available in the Source data file.

Back to article page